JP2022534420A5 - - Google Patents
Info
- Publication number
- JP2022534420A5 JP2022534420A5 JP2021570895A JP2021570895A JP2022534420A5 JP 2022534420 A5 JP2022534420 A5 JP 2022534420A5 JP 2021570895 A JP2021570895 A JP 2021570895A JP 2021570895 A JP2021570895 A JP 2021570895A JP 2022534420 A5 JP2022534420 A5 JP 2022534420A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alkyl
- hydrogen
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855560P | 2019-05-31 | 2019-05-31 | |
| US62/855,560 | 2019-05-31 | ||
| PCT/US2020/035592 WO2020243720A1 (en) | 2019-05-31 | 2020-06-01 | Pharmacological agents for treating protein aggregation diseases of the eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534420A JP2022534420A (ja) | 2022-07-29 |
| JP2022534420A5 true JP2022534420A5 (enExample) | 2023-06-09 |
Family
ID=73553335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570895A Pending JP2022534420A (ja) | 2019-05-31 | 2020-06-01 | 眼のタンパク質凝集疾患を治療するための薬剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220241247A1 (enExample) |
| EP (1) | EP3976017A4 (enExample) |
| JP (1) | JP2022534420A (enExample) |
| CN (1) | CN114173771A (enExample) |
| BR (1) | BR112021024151A2 (enExample) |
| CA (1) | CA3141998A1 (enExample) |
| MX (1) | MX2021014682A (enExample) |
| WO (1) | WO2020243720A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512116A (ja) * | 2020-01-28 | 2023-03-23 | プロテゴ バイオファーマ， インコーポレイテッド | トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法 |
| CN116963727A (zh) * | 2020-11-13 | 2023-10-27 | 普莱克斯医药公司 | 用于治疗眼部病症的药剂 |
| WO2023278604A1 (en) * | 2021-06-29 | 2023-01-05 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating ophthalmic diseases |
| WO2023009585A2 (en) * | 2021-07-28 | 2023-02-02 | Protego Biopharma, Inc. | Transthyretin stabilizing compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005112913A1 (en) * | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
| WO2011116123A1 (en) * | 2010-03-19 | 2011-09-22 | Irm Llc | Tafamidis for the treatment of ophthalmic diseases |
| WO2013038351A1 (en) * | 2011-09-16 | 2013-03-21 | Pfizer Inc. | Solid forms of a transthyretin dissociation inhibitor |
| JP6068484B2 (ja) * | 2011-10-24 | 2017-01-25 | ソム、イノベーション、バイオテック、ソシエダッド、リミターダＳｏｍ Ｉｎｎｏｖａｔｉｏｎ Ｂｉｏｔｅｃｈ， Ｓ．Ｌ． | トランスサイレチン関連アミロイドーシスの新規療法 |
| US9499527B2 (en) * | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9169214B2 (en) * | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| JP2016514091A (ja) * | 2013-02-08 | 2016-05-19 | ミスフォールディング ダイアグノスティクス， インコーポレイテッド | トランスサイレチン抗体およびその使用 |
| BR112015021836A2 (pt) * | 2013-03-08 | 2017-07-18 | Allergan Inc | conjugados de antibióticos diretamente ligados com drogas esteroides |
| US9789091B2 (en) * | 2013-03-14 | 2017-10-17 | University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| US11872236B2 (en) * | 2018-04-05 | 2024-01-16 | Calasia Pharmaceuticals, Inc. | Pharmacological agents for treating ocular diseases |
-
2020
- 2020-06-01 MX MX2021014682A patent/MX2021014682A/es unknown
- 2020-06-01 CN CN202080054595.2A patent/CN114173771A/zh active Pending
- 2020-06-01 BR BR112021024151A patent/BR112021024151A2/pt not_active Application Discontinuation
- 2020-06-01 US US17/615,469 patent/US20220241247A1/en not_active Abandoned
- 2020-06-01 JP JP2021570895A patent/JP2022534420A/ja active Pending
- 2020-06-01 WO PCT/US2020/035592 patent/WO2020243720A1/en not_active Ceased
- 2020-06-01 EP EP20813466.8A patent/EP3976017A4/en not_active Withdrawn
- 2020-06-01 CA CA3141998A patent/CA3141998A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063088A5 (enExample) | ||
| CN116249683A8 (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
| RU2011103741A (ru) | Композиции и способы лечения заболевания сетчатки | |
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| JP2022000482A5 (enExample) | ||
| JP2023546565A5 (enExample) | ||
| JP2017502073A5 (enExample) | ||
| JP2008509187A5 (enExample) | ||
| JPH08510479A (ja) | 眼の炎症障害を処置するための３‐ベンゾイルフェニル酢酸誘導体を含む局所的に投与可能な組成物 | |
| JP2006515838A5 (enExample) | ||
| JPH06100446A (ja) | （Ｓ）−α−フルオロメチル−ヒスチジン及びそのエステルを使用するぜん息の治療方法 | |
| EA200900827A1 (ru) | Фармацевтический состав, содержащий антагонист нейрокининов | |
| CN111295202A (zh) | 治疗甲癣的外用制剂 | |
| JP2019515040A5 (enExample) | ||
| JP2024541569A5 (enExample) | ||
| JP2002525318A (ja) | 眼、耳および鼻治療用の抗生物質組成物 | |
| WO2010075315A2 (en) | Topical formulations of flap inhibitors for administration to an eye | |
| EP2983788A1 (en) | The local treatment of inflammatory ophthalmic diseases | |
| RU99121654A (ru) | Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки | |
| JP2005508341A5 (enExample) | ||
| JP5955774B2 (ja) | プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法 | |
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы | |
| JP5746224B2 (ja) | ミラミスチンを含有する薬剤 | |
| JP2021512898A5 (enExample) | ||
| JP2018519252A5 (enExample) |